B. Polistena, “The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri® PharmacoEconomics (TyPE) Study”, Grhta, vol. 6, no. 1, Jun. 2019.